Our study identified that HERC2 serves as an opposing force actively participating in the homeostatic control of PD-L1 in HCC, and interfering with the expression or function of HERC2 might help promote the anti-tumor efficiency of immune checkpoint-based therapy. The gene discussed is HERC2; the disease is hepatocellular carcinoma.